Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY111 Variant

NCT06701396

Status	RECRUITING
Phase	Phase 3
Sponsor	Vanda Pharmaceuticals
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (5)

- Ability and acceptance to provide written informed consent.
- A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).
- Carrier of CRY1”11variant.
- Men or women between 18 - 75 years, inclusive.
- Body Mass Index (BMI) of e 18 and d 40 kg/m\^2.

Exclusion (4)

- Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.
- Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.
- A positive test for substances of abuse.
- Current tobacco user.

Locations (1 total)

Vanda Investigational Site, Çankaya, Ankara, Turkey (Türkiye)

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.